Cardiovascular and autonomic phenotype of db/db diabetic mice

Experimental Physiology

Volumn 94, Issue 6, 2009, Pages 648-658

  Senador, Danielle ^a   Kanakamedala, Keerthy ^a   Irigoyen, Maria Claudia ^b   Morris, Mariana ^a   Elased, Khalid M ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; GLUCOSE; INSULIN; LOSARTAN;

AGING; ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTONOMIC NERVOUS SYSTEM; AUTONOMIC NERVOUS SYSTEM FUNCTION; BLOOD PRESSURE MONITORING; BLOOD PRESSURE VARIABILITY; BODY WEIGHT; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; CHRONIC DRUG ADMINISTRATION; CIRCADIAN RHYTHM; CONTROLLED STUDY; DARKNESS; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HEART RATE; HEART RATE VARIABILITY; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; LOCOMOTION; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PHENOTYPE; PRESSORECEPTOR REFLEX; PULSE RATE; RECEPTOR BLOCKING; SYSTOLIC BLOOD PRESSURE; TELEMETRY; TREATMENT DURATION;

EID: 65649109348     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2008.046474     Document Type: Article

References (58)

1. Aasum E, Hafstad AD, Severson DL Larsen TS (2003). Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes 52, 434 441. (Pubitemid 36173200)
2. Amazonas RB Lopes De Faria JB (2006). Effects of tight blood pressure control on glomerular hypertrophy in a model of genetic hypertension and experimental diabetes mellitus. Life Sci 79, 2135 2143. (Pubitemid 44573276)
3. Bagi Z, Erdei N, Toth A, Li W, Hintze TH, Koller A Kaley G (2005). Type 2 diabetic mice have increased arteriolar tone and blood pressure: enhanced release of COX-2-derived constrictor prostaglandins. Arterioscler Thromb Vasc Biol 25, 1610 1616. (Pubitemid 41098929)
4. Balbinott AW, Irigoyen MC, Brasileiro-Santos MS, Zottis B, De Lima NG, Passaglia J Schaan BD (2005). Dose-dependent autonomic dysfunction in chronic l-NAME-hypertensive diabetic rats. J Cardiovasc Pharmacol 46, 563 569. (Pubitemid 41527747)
5. Belmadani S, Palen DI, Gonzalez-Villalobos RA, Boulares HA Matrougui K (2008). Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice. Diabetes 57, 1629 1637.
6. Bodary PF, Shen Y, Ohman M, Bahrou KL, Vargas FB, Cudney SS, Wickenheiser KJ, Myers MG Jr. Eitzman DT (2007). Leptin regulates neointima formation after arterial injury through mechanisms independent of blood pressure and the leptin receptor/STAT3 signaling pathways involved in energy balance. Arterioscler Thromb Vasc Biol 27, 70 76. (Pubitemid 46360382)
7. Brezniceanu ML, Liu F, Wei CC, Chenier I, Godin N, Zhang SL, Filep JG, Ingelfinger JR Chan JS (2008). Attenuation of interstitial fibrosis and tubular apoptosis in db/db transgenic mice overexpressing catalase in renal proximal tubular cells. Diabetes 57, 451 459.
8. 2 knockout mice subjected to a high-salt diet. Clin Sci (Lond) 103 (Suppl 48 380S 384S.
9. Campbell DJ, Rong P, Kladis A, Rees B, Ganten D Skinner SL (1995). Angiotensin and bradykinin peptides in the TGR (mRen-2)27 rat. Hypertension 25, 1014 1020.
10. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI Morgenstern JP (1996). Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84, 491 495. (Pubitemid 26060722)
11. Chu KY, Lau T, Carlsson PO Leung PS (2006). Angiotensin II type 1 receptor blockade improves β-cell function and glucose tolerance in a mouse model of type-2 diabetes. Diabetes 55, 367 374. (Pubitemid 43343265)
12. Coleman DL (1978). Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 14, 141 148. (Pubitemid 8286141)
13. Coleman DL (1983). Lessons from studies with genetic forms of diabetes in the mouse. Metabolism 32, 162 164.
14. Dluhy RG McMahon GT (2008). Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 358, 2630 2633.
15. Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, Perreault M, Wang S Tobin JF (2006). Molecular activation of PPARγ by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 45, 154 162.
16. Farah V, Elased KM, Chen Y, Key MP, Cunha TS, Irigoyen MC Morris M (2006). Nocturnal hypertension in mice consuming a high fructose diet. Auton Neurosci 130, 41 50.
17. Farah V, Elased KM Morris M (2007a). Genetic and dietary interactions: role of angiotensin AT1a receptors in response to a high-fructose diet. Am J Physiol Heart Circ Physiol 293, H1083 H1089. (Pubitemid 47254208)
18. Farah VM, De AK, Joaquim LF, Candido GO, Bernardes N, Fazan R Jr., Schaan BD Irigoyen MC (2007b). Autonomic modulation of arterial pressure and heart rate variability in hypertensive diabetic rats. Clinics 62, 477 482.
19. Fogari R, Zoppi A, Lazzari P, Preti P, Mugellini A, Corradi L Lusardi P (1998). ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 32, 616 620. (Pubitemid 28440963)
20. Gerstein HC, Riddle MC, Kendall DM, Cohen RM, Goland R, Feinglos MN, Kirk JK, Hamilton BP, Ismail-Beigi F Feeney P (2007). Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99, 34i 43i. (Pubitemid 46961884)
21. Gilbert RE, Krum H, Wilkinson-Berka J Kelly DJ (2003). The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. Diabet Med 20, 607 621. (Pubitemid 36966554)
22. Guo C, Martinez-Vasquez D, Mendez GP, Toniolo MF, Yao TM, Oestreicher EM, Kikuchi T, Lapointe N, Pojoga L, Williams GH, Ricchiuti V Adler GK (2006). Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 147, 5363 5373.
23. Guo Z, Su W, Allen S, Pang H, Daugherty A, Smart E Gong MC (2005). COX-2 up-regulation and vascular smooth muscle contractile hyperreactivity in spontaneous diabetic db/db mice. Cardiovasc Res 67, 723 735. (Pubitemid 41033368)
24. 1 receptor antagonism normalizes retinal blood flow and acetylcholine-induced vasodilatation in normotensive diabetic rats. Diabetologia 47, 113 123. (Pubitemid 38141947)
25. Hummel KP, Dickie MM Coleman DL (1966). Diabetes, a new mutation in the mouse. Science 153, 1127 1128.
26. Iyer SN Katovich MJ (1996). Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats. Am J Hypertens 9, 662 668. (Pubitemid 26266604)
27. Kanakamedala K, Senador D, Zhang WF, Morris M Elased KM (2007). Increased ACE activity in young normotensive diabetic (db/db) mice. Hypertension 50, E134. (Pubitemid 46571016)
28. Kanie N Kamata K (2000). Contractile responses in spontaneously diabetic mice. I. Involvement of superoxide anion in enhanced contractile response of aorta to norepinephrine in C57BL/KsJ(db/db) mice. Gen Pharmacol 35, 311 318. (Pubitemid 34258513)
29. Kosugi R, Shioi T, Watanabe-Maeda K, Yoshida Y, Takahashi K, Machida Y Izumi T (2006). Angiotensin II receptor antagonist attenuates expression of aging markers in diabetic mouse heart. Circ J 70, 482 488.
30. Krege JH, Kim HS, Moyer JS, Jennette JC, Peng L, Hiller SK Smithies O (1997). Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis. Hypertension 29, 150 177. (Pubitemid 27074036)
31. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, Devereux RB, Beevers G, De Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM Snapinn S (2002). Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 20, 1879 1886.
32. Mark AL, Shaffer RA, Correia ML, Morgan DA, Sigmund CD Haynes WG (1999). Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J Hypertens 17, 1949 1953. (Pubitemid 30345336)
33. Mathew R, Futterweit S, Valderrama E, Tarectecan AA, Bylander JE, Bond JS Trachtman H (2005). Meprin-α in chronic diabetic nephropathy: interaction with the renin-angiotensin axis. Am J Physiol Renal Physiol 289, F911 F921. (Pubitemid 41324212)
34. Moan A, Hoieggen A, Seljeflot I, Risanger T, Arnesen H Kjeldsen SE (1996). The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 14, 1093 1097. (Pubitemid 26329286)
35. Moriyama T, Oka K, Ueda H Imai E (2004). Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes. Clin Exp Nephrol 8, 230 236. (Pubitemid 39421372)
36. Nakano S, Fukuda M, Hotta F, Ito T, Ishii T, Kitazawa M, Nishizawa M, Kigoshi T Uchida K (1998). Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects. Diabetes 47, 1501 1506. (Pubitemid 28396956)
37. Neels HM, Scharpe SL, Van Sande ME, Verkerk RM Van Acker KJ (1982). Improved micromethod for assay of serum angiotensin converting enzyme. Clin Chem 28, 1352 1355.
38. Nielsen B, Gronbaek H, Osterby R Flyvbjerg A (2003). Effect of combination therapy with a calcium channel blocker and an angiotensin-converting enzyme inhibitor on renal hypertrophy and urinary albumin excretion in diabetic rats. Exp Diabesity Res 4, 191 199. (Pubitemid 37483656)
39. Park S, Bivona BJ, Feng Y, Lazartigues E Harrison-Bernard LM (2008). Intact renal afferent arteriolar autoregulatory responsiveness in db/db mice. Am J Physiol Renal Physiol 295, F1504 F1511.
40. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R Travert F (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358, 2560 2572.
41. Rahmouni K, Morgan DA, Morgan GM, Mark AL Haynes WG (2005). Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes 54, 2012 2018. (Pubitemid 40911263)
42. Raimondi L, De PP, Mannucci E, Lonardo G, Sartiani L, Banchelli G, Pirisino R, Mugelli A Cerbai E (2004). Restoration of cardiomyocyte functional properties by angiotensin II receptor blockade in diabetic rats. Diabetes 53, 1927 1933. (Pubitemid 38857056)
43. Schroeder EB, Chambless LE, Liao D, Prineas RJ, Evans GW, Rosamond WD Heiss G (2005). Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 28, 668 674. (Pubitemid 40315330)
44. Semeniuk LM, Kryski AJ Severson DL (2002). Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. Am J Physiol Heart Circ Physiol 283, H976 H982.
45. Senador D, Farah V, Mariana M Irigoyen MC (2006). High fructose diet enhances Losartan's hypotensive effect. Hypertension 48, E89 E90.
46. Senador D, Oroszi T, Key M, Elased KM Morris M (2007). Angiotensinergic control of blood pressure in mice overexpressing ACE. Hypertension 50, E143.
47. Shao J, Iwashita N, Ikeda F, Ogihara T, Uchida T, Shimizu T, Uchino H, Hirose T, Kawamori R Watada H (2006). Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on β-cell function and morphology in db/db mice. Biochem Biophys Res Commun 344, 1224 1233.
48. Sowers JR (2004). Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 286, H1597 H1602. (Pubitemid 38525443)
49. Stauss HM (2007). Power spectral analysis in mice: what are the appropriate frequency bands? Am J Physiol Regul Integr Comp Physiol 292, R902 R903. (Pubitemid 46207746)
50. Su W, Guo Z, Randall DC, Cassis L, Brown DR Gong MC (2008). Hypertension and disrupted blood pressure circadian rhythm in Type 2 diabetic db/db mice. Am J Physiol Heart Circ Physiol 295, H1634 H1641.
51. Sugaru E, Nakagawa T, Ono-Kishino M, Nagamine J, Tokunaga T, Kitoh M, Hume WE, Nagata R Taiji M (2007). Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice. Nephron Exp Nephrol 105, e45 e52. (Pubitemid 46150849)
52. Sullivan KA, Hayes JM, Wiggin TD, Backus C, Su OS, Lentz SI, Brosius F 3rd. Feldman EL (2007). Mouse models of diabetic neuropathy. Neurobiol Dis 28, 276 285. (Pubitemid 350116599)
53. Tamura K, Tsurumi Y, Sakai M, Tanaka Y, Okano Y, Yamauchi J, Ishigami T, Kihara M, Hirawa N, Toya Y, Yabana M, Tokita Y, Ohnishi T Umemura S (2007). A possible relationship of nocturnal blood pressure variability with coronary artery disease in diabetic nephropathy. Clin Exp Hypertens 29, 31 42.
54. UK Prospective Diabetes Study (UKPDS) Group (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837 853. (Pubitemid 28416718)
55. Vita G, Bellinghieri G, Trusso A, Costantino G, Santoro D, Monteleone F, Messina C Savica V (1999). Uremic autonomic neuropathy studied by spectral analysis of heart rate. Kidney Int 56, 232 237. (Pubitemid 29300539)
56. Wichi RB, Farah V, Chen Y, Irigoyen MC Morris M (2007). Deficiency in angiotensin AT1a receptors prevents diabetes-induced hypertension. Am J Physiol Regul Integr Comp Physiol 292, R1184 R1189. (Pubitemid 46377083)
57. Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, Coffman TM, Chen S Batlle D (2006). ACE and ACE2 activity in diabetic mice. Diabetes 55, 2132 2139. (Pubitemid 44509989)
58. Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB, Olofsson B, Probstfield J McMurray JV (2005). Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 112, 48 53. (Pubitemid 40962568)